Trials / Completed
CompletedNCT00174304
Open Label Study To Assess The Effectiveness Of Amlodipine-Atorvastatin Combination In Hypertension And Dyslipidemia.
An International, Multicentre, Open Label Study To Assess The Effectiveness Of Amlodipine/Atorvastatin Combination In Subjects With Hypertension And Dyslipidaemia. (The JEWEL II Study)
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 1,120 (planned)
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the effectiveness of amlodipine/atorvastatin therapy by assessing the percentage of subjects who reach target blood pressure (BP) and LDL-C targets as defined by their governing guidelines.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Amlodipine/atorvastatin single pill |
Timeline
- Start date
- 2004-10-01
- Completion
- 2006-09-01
- First posted
- 2005-09-15
- Last updated
- 2021-01-27
Locations
102 sites across 11 countries: Austria, Belgium, Finland, Greece, Hungary, Ireland, Italy, Portugal, Slovenia, Spain, Switzerland
Source: ClinicalTrials.gov record NCT00174304. Inclusion in this directory is not an endorsement.